Newport Laboratories releases new Mycoplasma bovis Test
Worthington, Minn. (November 9, 2015) – Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences.
This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines. The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).
“This is a great leap forward in our ability to compare Mycoplasma bovis isolates,” said Randy Shirbroun DVM, Director of Diagnostics, Newport Laboratories. “This new technology and its application to what we do further distinguishes Newport Labs.”
"The use of molecular biology in diagnostics is important in the detection, identification, characterization, and comparison of pathogens. It also aids in the selection of appropriate seed isolates for potential autogenous vaccine production through comparison of isolates, assuring that the genetic variation detected in multiple diagnostic cases submitting by a veterinarian will be represented. For organisms like Mycoplasma bovis and Histophilus somni, strain variation, or 'heterosis', must be considered in the design of such vaccines" (Howard, et al, Journal of Clinical Microbiology, 2000).
Newport Laboratories, Inc., located in Worthington, Minnesota and owned by Merial, Inc., will begin use of this advanced diagnostic technology for Mycoplasma bovis this fall.